DE60142197D1 - Pharmazeutische Zusammensetzung - Google Patents
Pharmazeutische ZusammensetzungInfo
- Publication number
- DE60142197D1 DE60142197D1 DE60142197T DE60142197T DE60142197D1 DE 60142197 D1 DE60142197 D1 DE 60142197D1 DE 60142197 T DE60142197 T DE 60142197T DE 60142197 T DE60142197 T DE 60142197T DE 60142197 D1 DE60142197 D1 DE 60142197D1
- Authority
- DE
- Germany
- Prior art keywords
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0025354.2A GB0025354D0 (en) | 2000-10-17 | 2000-10-17 | Chemical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60142197D1 true DE60142197D1 (de) | 2010-07-01 |
Family
ID=9901397
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60142197T Expired - Lifetime DE60142197D1 (de) | 2000-10-17 | 2001-10-12 | Pharmazeutische Zusammensetzung |
DE60106287T Expired - Lifetime DE60106287T2 (de) | 2000-10-17 | 2001-10-12 | Chemische verbindungen |
DE60127002T Expired - Lifetime DE60127002T2 (de) | 2000-10-17 | 2001-10-12 | Pharmazeutische zusammensetzung |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60106287T Expired - Lifetime DE60106287T2 (de) | 2000-10-17 | 2001-10-12 | Chemische verbindungen |
DE60127002T Expired - Lifetime DE60127002T2 (de) | 2000-10-17 | 2001-10-12 | Pharmazeutische zusammensetzung |
Country Status (29)
Country | Link |
---|---|
US (5) | US7119092B2 (de) |
EP (4) | EP1752449A1 (de) |
JP (1) | JP3940359B2 (de) |
KR (1) | KR100847414B1 (de) |
CN (1) | CN1231468C (de) |
AR (1) | AR034268A1 (de) |
AT (3) | ATE468324T1 (de) |
AU (4) | AU9572301A (de) |
BR (1) | BR0114637A (de) |
CA (1) | CA2425876C (de) |
CY (1) | CY1107634T1 (de) |
CZ (1) | CZ299824B6 (de) |
DE (3) | DE60142197D1 (de) |
DK (2) | DK1524266T3 (de) |
ES (3) | ES2282794T3 (de) |
GB (1) | GB0025354D0 (de) |
HK (2) | HK1058788A1 (de) |
HU (1) | HU228146B1 (de) |
IL (3) | IL155165A0 (de) |
MX (1) | MXPA03003536A (de) |
MY (1) | MY124957A (de) |
NO (1) | NO324468B1 (de) |
NZ (1) | NZ525091A (de) |
PL (1) | PL203071B1 (de) |
PT (2) | PT1524266E (de) |
SI (2) | SI1326832T1 (de) |
TW (1) | TWI299730B (de) |
WO (1) | WO2002032867A1 (de) |
ZA (1) | ZA200302801B (de) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE39921E1 (en) | 1999-10-07 | 2007-11-13 | Smithkline Beecham Corporation | Chemical compounds |
GB9923748D0 (en) | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
GB0025354D0 (en) | 2000-10-17 | 2000-11-29 | Glaxo Group Ltd | Chemical compounds |
GB0108595D0 (en) | 2001-04-05 | 2001-05-23 | Glaxo Group Ltd | Chemical compounds |
GB0119797D0 (en) | 2001-08-14 | 2001-10-03 | Glaxo Group Ltd | Chemical compounds |
GB0203020D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
GB0203022D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
EP1472222A1 (de) | 2002-02-08 | 2004-11-03 | Glaxo Group Limited | Piperidylcarbonsäure amidderivate und deren verwendung zur behandlung von durch tachykinin vermittelten erkrankungen |
TWI283241B (en) * | 2002-05-29 | 2007-07-01 | Tanabe Seiyaku Co | Novel piperidine compound |
JP4079727B2 (ja) | 2002-09-06 | 2008-04-23 | セントラル硝子株式会社 | 光学活性1−(フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル)アルキルアミンn−モノアルキル誘導体とその製造方法 |
JO2696B1 (en) | 2002-12-23 | 2013-03-03 | شركة جانسين فارماسوتيكا ان. في | Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists |
JP4660199B2 (ja) * | 2002-12-23 | 2011-03-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換1−ピペリジン−4−イル−4−アゼチジン−3−イル−ピペラジン誘導体およびそれらのニューロキニン拮抗薬としての使用 |
JO2485B1 (en) * | 2002-12-23 | 2009-01-20 | شركة جانسين فارماسوتيكا ان. في | 1-Piperidine-3-Yl-4-Piperidine-4-Yl-Piperazine derivatives substituted and used as quinine antagonists |
JP4677235B2 (ja) * | 2002-12-23 | 2011-04-27 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換4−(4−ピペリジン−4−イル−ピペラジン−1−イル)−アゼパン誘導体およびそれらのニューロキニン拮抗薬としての使用 |
WO2004067093A2 (en) * | 2003-01-27 | 2004-08-12 | Glaxo Group Limited | Nk1 receptor antagonists for the treatment of functional dyspepsia |
FR2853648B1 (fr) * | 2003-04-11 | 2006-08-18 | Fournier Lab Sa | Nouveaux derives de benzenesulfonamides et leur utilisation en therapeutique |
WO2004087685A2 (en) * | 2003-03-31 | 2004-10-14 | Janssen Pharmaceutica N.V. | Phospholipase c inhibitors for use in treating inflammatory disorders |
WO2004089901A2 (en) * | 2003-03-31 | 2004-10-21 | Janssen Pharmaceutica N.V. | Phospholipase c inhibitors for use in treating inflammatory disorders |
US7262197B2 (en) | 2003-03-31 | 2007-08-28 | Janssen Pharmaceutica, N.V | Phospholipase C inhibitors for use in treating inflammatory disorders |
GB0308968D0 (en) * | 2003-04-17 | 2003-05-28 | Glaxo Group Ltd | Medicaments |
DE602004013772D1 (de) * | 2003-06-10 | 2008-06-26 | Janssen Pharmaceutica Nv | Kombination von opioiden und einem piperazin-derivat für die behandlung von schmerzen |
EP1638935A1 (de) * | 2003-06-19 | 2006-03-29 | Pfizer Products Inc. | Nk1 antagonisten |
JO2525B1 (en) * | 2004-04-08 | 2010-03-17 | شركة جانسين فارماسوتيكا ان. في | Derived 4-alkyl-and-4-canoelperidine derivatives and their use as anti-neroquin |
WO2006062110A1 (ja) * | 2004-12-06 | 2006-06-15 | Banyu Pharmaceutical Co., Ltd. | ピペラジン誘導体 |
GB0426942D0 (en) * | 2004-12-08 | 2005-01-12 | Glaxo Group Ltd | Medicament |
ATE478075T1 (de) | 2005-03-08 | 2010-09-15 | Janssen Pharmaceutica Nv | Diazaspiro-ä4,4ü-nonanderivate als neurokinin- (nk1)-antagonisten |
GB0514705D0 (en) * | 2005-07-18 | 2005-08-24 | Glaxo Group Ltd | Chemical compounds |
GB0514707D0 (en) * | 2005-07-18 | 2005-08-24 | Glaxo Group Ltd | Chemical compounds |
GB0514704D0 (en) * | 2005-07-18 | 2005-08-24 | Glaxo Group Ltd | Chemical compounds |
JP4904945B2 (ja) | 2006-06-30 | 2012-03-28 | セントラル硝子株式会社 | 光学活性1−(フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル)アルキルアミンn−モノアルキル誘導体の製造方法 |
JP2010516734A (ja) | 2007-01-24 | 2010-05-20 | グラクソ グループ リミテッド | 3,5−ジアミノ−6−(2,3−ジクロロフェニル)−1,2,4−トリアジンまたはr(−)−2,4−ジアミノ−5−(2,3−ジクロロフェニル)−6−フルオロメチルピリミジンを含む医薬組成物 |
WO2009035652A1 (en) | 2007-09-13 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof |
GB0812849D0 (en) * | 2008-07-14 | 2008-08-20 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
DK2729147T3 (en) | 2011-07-04 | 2017-12-18 | Irbm - Science Park S P A | NK-1 RECEPTOR ANTAGONISTS FOR TREATMENT OF CORNOVA |
EP2817312B1 (de) | 2012-02-22 | 2016-02-17 | Leo Pharma A/S | Neuartige neurokinin-1 rezeptorantagonistenverbindungen |
WO2015024203A1 (en) | 2013-08-20 | 2015-02-26 | Leo Pharma A/S | Novel neurokinin 1 receptor antagonist compounds ii |
KR20200002899A (ko) | 2017-04-10 | 2020-01-08 | 체이스 테라퓨틱스 코포레이션 | 시누클레인병변을 치료하기 위한 nk1-길항제 배합물 및 방법 |
WO2019006050A1 (en) | 2017-06-30 | 2019-01-03 | Chase Therapeutics Corporation | NK-1 ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN TREATING DEPRESSION |
CN111116514B (zh) * | 2020-01-10 | 2024-03-19 | 广州科锐特生物科技有限公司 | 一种1-环丙甲酰基哌嗪盐酸盐的制备方法 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US536020A (en) * | 1894-04-09 | 1895-03-19 | Washing or bathing apparatus | |
US4410522A (en) | 1974-05-09 | 1983-10-18 | Toyama Chemical Co., Ltd. | Cephalosporins |
US4087424A (en) | 1974-05-09 | 1978-05-02 | Toyama Chemical Co., Ltd. | Novel penicillins and cephalosporins and process for producing the same |
US4110327A (en) | 1974-05-09 | 1978-08-29 | Toyama Chemical Co., Ltd. | 2,3 Diketo-piperazinocarbonylamino alkanoic acids and derivatives |
US4112090A (en) | 1974-05-09 | 1978-09-05 | Toyama Chemical Co., Ltd. | Novel penicillins and cephalosporins and process for producing the same |
US4219554A (en) | 1974-05-09 | 1980-08-26 | Toyama Chemical Company, Limited | Novel penicillins and cephalosporins and process for producing same |
US4379152A (en) | 1974-05-09 | 1983-04-05 | Toyama Chemical Co., Ltd. | Cephalosporins |
IL47168A (en) | 1974-05-09 | 1979-07-25 | Toyama Chemical Co Ltd | Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same |
US4327097A (en) | 1974-05-09 | 1982-04-27 | Toyama Chemical Co., Ltd. | Novel penicillins |
NO154582C (no) | 1978-10-20 | 1986-11-05 | Ferrosan Ab | Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider. |
JPS57118587A (en) | 1981-11-26 | 1982-07-23 | Toyama Chem Co Ltd | Novel penicillin |
US5028610A (en) | 1987-03-18 | 1991-07-02 | Sankyo Company Limited | N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use |
GB8709666D0 (en) | 1987-04-23 | 1987-05-28 | Beecham Group Plc | Compounds |
GB8713061D0 (en) | 1987-06-04 | 1987-07-08 | Beecham Group Plc | Compounds |
US5109014A (en) | 1990-12-10 | 1992-04-28 | Jacobson Richard M | N-aryl-3-aryl-4-substituted-2,3,4,5-tetrahydro-1H-pyrazole-1-carboxamides |
SE9100860D0 (sv) | 1991-03-22 | 1991-03-22 | Kabi Pharmacia Ab | New use |
ATE195867T1 (de) | 1991-09-20 | 2000-09-15 | Glaxo Group Ltd | Neue medizinische indikation für tachykinin- antagonisten |
CA2083891A1 (en) | 1991-12-03 | 1993-06-04 | Angus Murray Macleod | Heterocyclic compounds, compositions containing them and their use in therapy |
US5334387A (en) * | 1993-02-23 | 1994-08-02 | Colgate-Palmolive Company | Topical composition comprising mono and dialkyl phosphates with a cosurfactant |
US5563127A (en) | 1993-03-24 | 1996-10-08 | The Dupont Merck Pharmaceutical Company | Boronic acid and ester inhibitors of thrombin |
US5348955A (en) | 1993-06-22 | 1994-09-20 | Merck & Co., Inc. | N,N-diacylpiperazines |
EP0655422B1 (de) | 1993-11-26 | 1998-08-12 | Deutsche Rockwool Mineralwoll-GmbH | Verfahren zum Herstellen einer Schmelze für die Mineralfaserherstellung |
IL111730A (en) * | 1993-11-29 | 1998-12-06 | Fujisawa Pharmaceutical Co | Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them |
IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
US5464788A (en) | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
DE4425146A1 (de) | 1994-07-15 | 1996-01-18 | Basf Ag | Verwendung heterocyclischer Verbindungen |
US5814636A (en) | 1994-07-15 | 1998-09-29 | Meiji Seika Kabushiki Kaisha | Compounds with platelet aggregation inhibitor activity |
WO1996003378A1 (fr) | 1994-07-26 | 1996-02-08 | Sankyo Company, Limited | Derives d'amide n-phenyle et d'uree |
US5696123A (en) | 1994-09-17 | 1997-12-09 | Boehringer Ingelheim Kg | Neurokinin antagonists |
DE19520499C2 (de) | 1994-09-17 | 2003-06-18 | Boehringer Ingelheim Kg | Neurokinin-Antagonisten, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende pharmazeutische Zusammensetzungen sowie ihre Verwendung |
JPH10506399A (ja) | 1994-09-30 | 1998-06-23 | ノバルティス アクチェンゲゼルシャフト | 1−アシル−4−マリファチルアミノピペリジン化合物 |
US5998444A (en) | 1995-10-24 | 1999-12-07 | Zeneca Ltd. | Piperidinyl compounds as NK1 or NK2 antagonists |
DE69534213T2 (de) | 1994-10-25 | 2006-01-12 | Astrazeneca Ab | Therapeutisch wirksame Heterocyclen |
US5629322A (en) | 1994-11-15 | 1997-05-13 | Merck & Co., Inc. | Cyclic amidine analogs as inhibitors of nitric oxide synthase |
US5576317A (en) | 1994-12-09 | 1996-11-19 | Pfizer Inc. | NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis |
US5700801A (en) | 1994-12-23 | 1997-12-23 | Karl Thomae, Gmbh | Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
CZ189197A3 (cs) | 1994-12-23 | 1998-01-14 | Dr. Karl Thomae Gmbh | Piperazinové deriváty, způsob výroby a farmaceutický prostředek s jejich obsahem |
IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
NZ321575A (en) * | 1995-10-30 | 1999-05-28 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives |
DE19608665A1 (de) | 1996-03-06 | 1997-09-11 | Boehringer Ingelheim Kg | Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
US6057323A (en) | 1996-03-08 | 2000-05-02 | Adolor Corporation | Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith |
EP0891349A4 (de) | 1996-04-03 | 2001-01-24 | Merck & Co Inc | Inhibitoren von farnesylprotein-transferase |
CA2249559A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
JP2000507582A (ja) | 1996-04-03 | 2000-06-20 | メルク エンド カンパニー インコーポレーテッド | ファルネシルプロテイントランスフェラーゼの阻害剤 |
US5859012A (en) | 1996-04-03 | 1999-01-12 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1998001133A1 (fr) | 1996-07-08 | 1998-01-15 | Yamanouchi Pharmaceutical Co., Ltd. | Inhibiteurs de la resorption osseuse |
US6117855A (en) | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
US5929077A (en) | 1996-11-08 | 1999-07-27 | Leftheris; Katerina | Thioproline-containing inhibitors of farnesyl protein transferase |
US5977104A (en) | 1996-12-02 | 1999-11-02 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptor antagonists for treating bipolar disorders |
US6114315A (en) | 1996-12-02 | 2000-09-05 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety |
AU731672B2 (en) | 1996-12-02 | 2001-04-05 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating bipolar disorders |
AUPO735997A0 (en) | 1997-06-17 | 1997-07-10 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives |
EP1014984A1 (de) | 1997-08-27 | 2000-07-05 | Merck & Co., Inc. | Prenyl-protein transferase inhibitoren |
ATE267168T1 (de) | 1997-11-24 | 2004-06-15 | Merck & Co Inc | Beta-alanin-derivate als zell-adhäsions- inhibitoren |
GB9923748D0 (en) | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
US6253732B1 (en) * | 1999-11-11 | 2001-07-03 | Ford Global Technologies, Inc. | Electronic throttle return mechanism with a two-spring and two-lever default mechanism |
GB0025354D0 (en) * | 2000-10-17 | 2000-11-29 | Glaxo Group Ltd | Chemical compounds |
US20030022891A1 (en) | 2000-12-01 | 2003-01-30 | Anandan Palani | MCH antagonists and their use in the treatment of obesity |
GB0203022D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
MY141736A (en) | 2002-10-08 | 2010-06-15 | Elanco Animal Health Ireland | Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists |
-
2000
- 2000-10-17 GB GBGB0025354.2A patent/GB0025354D0/en not_active Ceased
-
2001
- 2001-10-12 DK DK04077714T patent/DK1524266T3/da active
- 2001-10-12 DE DE60142197T patent/DE60142197D1/de not_active Expired - Lifetime
- 2001-10-12 IL IL15516501A patent/IL155165A0/xx active IP Right Grant
- 2001-10-12 EP EP06122021A patent/EP1752449A1/de not_active Withdrawn
- 2001-10-12 AT AT08151841T patent/ATE468324T1/de not_active IP Right Cessation
- 2001-10-12 US US10/398,264 patent/US7119092B2/en not_active Expired - Fee Related
- 2001-10-12 AT AT01976453T patent/ATE278669T1/de active
- 2001-10-12 DE DE60106287T patent/DE60106287T2/de not_active Expired - Lifetime
- 2001-10-12 KR KR1020037005286A patent/KR100847414B1/ko not_active IP Right Cessation
- 2001-10-12 PT PT04077714T patent/PT1524266E/pt unknown
- 2001-10-12 PL PL361180A patent/PL203071B1/pl unknown
- 2001-10-12 ES ES04077714T patent/ES2282794T3/es not_active Expired - Lifetime
- 2001-10-12 EP EP08151841A patent/EP1921064B1/de not_active Expired - Lifetime
- 2001-10-12 EP EP04077714A patent/EP1524266B1/de not_active Expired - Lifetime
- 2001-10-12 SI SI200130206T patent/SI1326832T1/xx unknown
- 2001-10-12 CA CA002425876A patent/CA2425876C/en not_active Expired - Fee Related
- 2001-10-12 SI SI200130727T patent/SI1524266T1/sl unknown
- 2001-10-12 ES ES01976453T patent/ES2227287T3/es not_active Expired - Lifetime
- 2001-10-12 AU AU9572301A patent/AU9572301A/xx active Pending
- 2001-10-12 MX MXPA03003536A patent/MXPA03003536A/es active IP Right Grant
- 2001-10-12 BR BR0114637-8A patent/BR0114637A/pt not_active Application Discontinuation
- 2001-10-12 CZ CZ20031082A patent/CZ299824B6/cs not_active IP Right Cessation
- 2001-10-12 ES ES08151841T patent/ES2346108T3/es not_active Expired - Lifetime
- 2001-10-12 DE DE60127002T patent/DE60127002T2/de not_active Expired - Lifetime
- 2001-10-12 CN CNB018175325A patent/CN1231468C/zh not_active Expired - Fee Related
- 2001-10-12 AT AT04077714T patent/ATE355271T1/de active
- 2001-10-12 AU AU2001295723A patent/AU2001295723B2/en not_active Ceased
- 2001-10-12 PT PT01976453T patent/PT1326832E/pt unknown
- 2001-10-12 NZ NZ525091A patent/NZ525091A/en not_active IP Right Cessation
- 2001-10-12 WO PCT/GB2001/004580 patent/WO2002032867A1/en active Application Filing
- 2001-10-12 HU HU0301459A patent/HU228146B1/hu not_active IP Right Cessation
- 2001-10-12 EP EP01976453A patent/EP1326832B1/de not_active Expired - Lifetime
- 2001-10-12 DK DK01976453T patent/DK1326832T3/da active
- 2001-10-12 JP JP2002536051A patent/JP3940359B2/ja not_active Expired - Fee Related
- 2001-10-15 AR ARP010104833A patent/AR034268A1/es not_active Application Discontinuation
- 2001-10-15 TW TW090125397A patent/TWI299730B/zh not_active IP Right Cessation
- 2001-10-15 MY MYPI20014779A patent/MY124957A/en unknown
-
2003
- 2003-03-31 IL IL155165A patent/IL155165A/en not_active IP Right Cessation
- 2003-04-07 NO NO20031561A patent/NO324468B1/no not_active IP Right Cessation
- 2003-04-10 ZA ZA200302801A patent/ZA200302801B/en unknown
-
2004
- 2004-01-13 HK HK04100241A patent/HK1058788A1/xx not_active IP Right Cessation
- 2004-11-22 US US10/994,605 patent/US7060702B2/en not_active Expired - Lifetime
-
2005
- 2005-05-23 HK HK05104289A patent/HK1075889A1/xx not_active IP Right Cessation
- 2005-08-24 AU AU2005204234A patent/AU2005204234B2/en not_active Ceased
-
2006
- 2006-02-21 US US11/358,631 patent/US7294630B2/en not_active Expired - Fee Related
-
2007
- 2007-05-21 CY CY20071100689T patent/CY1107634T1/el unknown
- 2007-10-01 US US11/865,211 patent/US7648990B2/en not_active Expired - Fee Related
-
2008
- 2008-05-15 IL IL191486A patent/IL191486A0/en unknown
-
2009
- 2009-04-09 AU AU2009201407A patent/AU2009201407B2/en not_active Ceased
- 2009-12-03 US US12/630,037 patent/US20100081667A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE355271T1 (de) | Pharmazeutische zusammensetzung | |
DE60106623D1 (de) | Neue pharmazeutische zusammensetzung | |
AT7729U3 (de) | Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat | |
ITTO20010008A0 (it) | Formulazione farmaceutica | |
FI20105657A (fi) | Farmaseuttisia koostumuksia | |
AR028204A1 (es) | Composiciones farmaceuticas electrohiladas | |
ATE404180T1 (de) | Geschmacksmaskierte pharmazeutische partikel | |
NO20025450L (no) | Ny farmasöytisk sammensetning | |
ITMI20010748A0 (it) | Composizioni farmaceutiche | |
NO20015175L (no) | Farmasöytisk sammensetning | |
ATE331529T1 (de) | Antigen enthaltende pharmazeutische zusammensetzung | |
NO20030627L (no) | Hydrogel-drevet medikament doseringsform | |
FI20011478A0 (fi) | Farmaseuttinen koostumus | |
ATE334656T1 (de) | Flüssige pharmazeutische zusammensetzung | |
ATE307571T1 (de) | Pharmazeutische formulierung enthaltend bicalutamid | |
EE05020B1 (et) | Glburiidi ravimkoostis | |
NO20026123L (no) | Farmasöytiske sammensetninger | |
ATE324883T1 (de) | Pharmazeutische zusammensetzung enthaltend lumiracoxib | |
ATE366128T1 (de) | Pharmazeutische zusammensetzung | |
FI20022128A (fi) | Farmaseuttinen koostumus | |
DE60217390D1 (de) | Bicalutamid enthaltende pharmazeutische zusammensetzung | |
FI4488U1 (fi) | Farmaseuttinen koostumus | |
DE10291905D2 (de) | Pharmazeutische Zusammensetzung | |
ATE350029T1 (de) | Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain | |
DE10107261B4 (de) | Pharmazeutische Zusammensetzung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |